BCL2 and acute lymphoblastic leukemia: Further, ETP-ALL is preferentially sensitive to BCL-2 inhibition [23,24,25], though recent data have shown that the spleen may represent a sanctuary site for residual disease in an ETP-ALL model treated with the BCL-2 inhibitor venetoclax as monotherapy [26].